Latest Mirum Pharmaceuticals News & Updates

See the latest news and media coverage for Mirum Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.

Mirum Pharmaceuticals

Rare disease biopharmaceutical company

mirumpharma.com

Headquarters: Foster City, United States
Founded year: 2018
Company type: Public company
Number of employees: 450–500
Industry: Pharmaceuticals

Last updated Today

Latest news about Mirum Pharmaceuticals

In short: Mirum Pharmaceuticals raised its 2026 sales guidance, reported positive clinical results for zilurgisertib, and appointed a new CMO.

Company announcements

September 8 Mirum Pharmaceuticals

Mirum Pharmaceuticals appoints Dr. Rob Myers as chief medical officer

Dr. Myers brings over two decades of experience in drug development and hepatology, joining from OrsoBio, while outgoing CMO Joanne Quan departs the company.

July 29 Mirum Pharmaceuticals

Mirum Pharmaceuticals reports Q2 2026 financial results and raises guidance

Net product sales reached $176.2 million, up 38% year-over-year; full-year guidance raised to $680-700 million; volixibat granted Breakthrough Therapy designation.

July 13 Mirum Pharmaceuticals

Mirum Pharmaceuticals reports inducement grants under Nasdaq rule

The awards include non-qualified stock options and RSUs to six new employees, with shares vesting over three to four years.

June 14 Mirum Pharmaceuticals

Mirum and Incyte announce positive Phase 2 results for zilurgisertib

FDA accepted NDA for zilurgisertib under Priority Review, with PDUFA date September 26, 2026.

Media coverage

Today Citeline

Zilurgisertib Among New EU Bone Disorder Drug Filings – US Verdict Nears

Mirum’s zilurgisertib and AstraZeneca's efzimfotase alfa – have entered the European Medicines Agency’s review process, ...

September 15 Seeking Alpha

Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst

Zilurgisertib is a once-daily oral ALK2 inhibitor under FDA review for fibrodysplasia ossificans progressiva, or FOP, in patients aged 12 and older. FOP is a...

August 22 The Globe and Mail

Mirum Pharmaceuticals Earnings Call Highlights Growth Momentum

Detailed price information for Mirum Pharmaceuticals Inc (MIRM-Q) from The Globe and Mail including charting and trades.

August 16 MarketBeat

Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell

Wall Street Zen lowered Mirum Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday.

Never miss news about Mirum Pharmaceuticals

Track Mirum Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Mirum Pharmaceuticals competitors & trending companies

Browse news for competitors to Mirum Pharmaceuticals and other trending companies.